AbbVie Inc, Common Stock






Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
Volume info-icon
This is the total number of shares traded during the most recent trading day.
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$130.75 L
$181.2 H

About AbbVie Inc, Common Stock

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. more

Industry: BiotechnologySector: Health Care


Time FrameABBVSectorS&P500
1-Week Return1.8%2.04%0.3%
1-Month Return2.51%1.29%3.13%
3-Month Return4.92%6.49%9.29%
6-Month Return5.82%5.65%17.55%
1-Year Return31.26%15.45%26.65%
3-Year Return63.16%19.73%33.3%
5-Year Return199.42%73.71%100.83%
10-Year Return364.99%180.12%238.73%


Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue33.27B45.80B56.20B58.05B54.32B[{"date":"2019-12-31","value":57.3,"profit":true},{"date":"2020-12-31","value":78.9,"profit":true},{"date":"2021-12-31","value":96.8,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":93.56,"profit":true}]
Cost of Revenue7.44B15.39B17.45B17.41B8.78B[{"date":"2019-12-31","value":42.64,"profit":true},{"date":"2020-12-31","value":88.2,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.82,"profit":true},{"date":"2023-12-31","value":50.33,"profit":true}]
Gross Profit25.83B30.42B38.75B40.64B45.54B[{"date":"2019-12-31","value":56.72,"profit":true},{"date":"2020-12-31","value":66.79,"profit":true},{"date":"2021-12-31","value":85.1,"profit":true},{"date":"2022-12-31","value":89.24,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin77.64%66.41%68.96%70.00%83.84%[{"date":"2019-12-31","value":92.61,"profit":true},{"date":"2020-12-31","value":79.21,"profit":true},{"date":"2021-12-31","value":82.25,"profit":true},{"date":"2022-12-31","value":83.5,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses12.46B17.86B19.86B21.83B28.11B[{"date":"2019-12-31","value":44.32,"profit":true},{"date":"2020-12-31","value":63.52,"profit":true},{"date":"2021-12-31","value":70.66,"profit":true},{"date":"2022-12-31","value":77.64,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income12.98B476.00M17.92B18.12B17.43B[{"date":"2019-12-31","value":71.66,"profit":true},{"date":"2020-12-31","value":2.63,"profit":true},{"date":"2021-12-31","value":98.93,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":96.18,"profit":true}]
Total Non-Operating Income/Expense(6.07B)642.00M(5.90B)(5.34B)(12.86B)[{"date":"2019-12-31","value":-944.86,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-918.54,"profit":false},{"date":"2022-12-31","value":-831.31,"profit":false},{"date":"2023-12-31","value":-2002.96,"profit":false}]
Pre-Tax Income8.43B3.40B12.99B13.48B6.25B[{"date":"2019-12-31","value":62.52,"profit":true},{"date":"2020-12-31","value":25.21,"profit":true},{"date":"2021-12-31","value":96.38,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":46.38,"profit":true}]
Income Taxes544.00M(1.22B)1.44B1.63B1.38B[{"date":"2019-12-31","value":33.33,"profit":true},{"date":"2020-12-31","value":-75,"profit":false},{"date":"2021-12-31","value":88.24,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":84.38,"profit":true}]
Income After Taxes7.88B4.62B11.55B11.85B4.87B[{"date":"2019-12-31","value":66.54,"profit":true},{"date":"2020-12-31","value":39.02,"profit":true},{"date":"2021-12-31","value":97.5,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.14,"profit":true}]
Income From Continuous Operations7.88B4.62B11.55B11.85B4.87B[{"date":"2019-12-31","value":66.54,"profit":true},{"date":"2020-12-31","value":39.02,"profit":true},{"date":"2021-12-31","value":97.5,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.14,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income7.88B4.62B11.54B11.84B4.86B[{"date":"2019-12-31","value":66.59,"profit":true},{"date":"2020-12-31","value":39,"profit":true},{"date":"2021-12-31","value":97.52,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.09,"profit":true}]
EPS (Diluted)8.9410.5112.6813.8711.11[{"date":"2019-12-31","value":64.46,"profit":true},{"date":"2020-12-31","value":75.78,"profit":true},{"date":"2021-12-31","value":91.42,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":80.1,"profit":true}]



These ratios help you determine the liquidity of the company. Higher is better.

Cash Ratio 0.44
Current Ratio 0.94
Quick Ratio 0.83

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ROA (LTM) 7.71%
ROE (LTM) 56.24%


These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

Debt Ratio Lower is generally better. Negative is bad. 0.95
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.05
Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. 18.59


These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

Trailing PE 50.57
Forward PE 14.58
P/S (TTM) 5.29
P/B 27.74
Price/FCF 78
EV/R 6.15
EV/Ebitda 19.45


AbbVie Seeking FDA And EMA Approval For Upadacitinib In Giant Cell Arteritis

WASHINGTON (dpa-AFX) - AbbVie, Inc. (ABBV) announced Friday that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EM…

12 Jul, 2024 a 1:06 pm Finanz Nachrichten

AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell Arteritis | ABBV Stock News

AbbVie seeks FDA and EMA approval for upadacitinib to treat giant cell arteritis, showing promising Phase 3 results with sustained remission and a consistent safety profile.

12 Jul, 2024 a 12:30 pm Stock Titan

AbbVie asks US Supreme Court to weigh protections for attorney records

Pharmaceutical company AbbVie has asked the U.S. Supreme Court to take up its fight to protect corporate records, warning that a lower court ruling threatens to erode the shield that keeps most attorney communications off-limits from a company''s courtroom opponents.

11 Jul, 2024 a 4:40 pm Reuters

Burn Pain Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight

Burn Pain companies are Takeda, Amgen, Novartis, AVEO Pharmaceuticals, Inc., Calithera Biosciences, Inc, AbbVie, Bristol-Myers Squibb, Abbott, and others. LAS VEGAS, NEVADA, UNITED STATES, July 10, 2024 /⁨EINPresswire.com⁩/ -- DelveInsight’s “Burn …

10 Jul, 2024 a 3:45 pm EIN News Pharmaceuticals

Multiple Myeloma Market Report 2034: Epidemiology, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight

Multiple Myeloma companies are BMS, Cartesian Therapeutics, AstraZeneca, Abbvie (Pharmacyclics), Johnson & Johnson, MorphoSys AG/I-Mab Biopharma, and others. LAS VEGAS, NEVADA, UNITED STATES, July 10, 2024 /⁨EINPresswire.com⁩/ -- …

10 Jul, 2024 a 12:00 pm EIN News Lung Cancer

AbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research & Development and Chief Scientific Officer | ABBV Stock News

AbbVie names Roopal Thakkar as EVP of R&D, bringing fresh perspectives to its global pipeline. CEO praises her strategic prowess amid Thomas Hudson''s retirement.

10 Jul, 2024 a 12:00 pm Stock Titan

AbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research & Development and Chief Scientific Officer

NORTH CHICAGO, Ill., July 10, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that Roopal Thakkar, M.D. who currently serves as senior vice president, chief medical officer, global therapeutics has been appointed to the position of executive vice president, research & development…

10 Jul, 2024 a 12:00 pm PR Newswire


What is AbbVie Inc share price today?

AbbVie Inc (ABBV) share price today is $170.28

Can Indians buy AbbVie Inc shares?

Yes, Indians can buy shares of AbbVie Inc (ABBV) on Vested. To buy AbbVie Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ABBV stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of AbbVie Inc be purchased?

Yes, you can purchase fractional shares of AbbVie Inc (ABBV) via the Vested app. You can start investing in AbbVie Inc (ABBV) with a minimum investment of $1.

How to invest in AbbVie Inc shares from India?

You can invest in shares of AbbVie Inc (ABBV) via Vested in three simple steps:

  • Click on Sign Up or Invest in ABBV stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in AbbVie Inc shares
What is AbbVie Inc 52-week high and low stock price?

The 52-week high price of AbbVie Inc (ABBV) is $181.2. The 52-week low price of AbbVie Inc (ABBV) is $130.75.

What is AbbVie Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of AbbVie Inc (ABBV) is 50.68

What is AbbVie Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of AbbVie Inc (ABBV) is 27.74

What is AbbVie Inc dividend yield?

The dividend yield of AbbVie Inc (ABBV) is 3.65%

What is the Market Cap of AbbVie Inc?

The market capitalization of AbbVie Inc (ABBV) is $300.69B

What is AbbVie Inc’s stock symbol?

The stock symbol (or ticker) of AbbVie Inc is ABBV

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare